CXCR4 and hematologic disorder: The CXCR4-targeting PET agent [68Ga]-Pentixafor has been administered to patients with various hematologic malignancies, allowing the identification of patients who can be treated with the therapeutic CXCR4-targeting radiotracer [90Y]/[177Lu]-Pentixafor.